-+ 0.00%
-+ 0.00%
-+ 0.00%

Bayer initiated a phase II clinical trial of an investigational inhibitor of G protein-coupled adduction potassium channel 4 in patients with atrial fibrillation.

Zhitongcaijing·09/09/2026 11:49:04
Listen to the news
Bayer initiated a phase II clinical trial of an investigational inhibitor of G protein-coupled adduction potassium channel 4 in patients with atrial fibrillation.